Business, energy, technology, markets and global industry news from Business News Today

COMP360

PharmaDeviceNews COMP360
Representative image showing neuroscience-based psychiatric treatment research as Evecxia Therapeutics builds the case for EVX-101 as a potential adjunctive therapy for patients with depression, obsessive-compulsive disorder and inadequate SSRI response.
Pharma & Biotech

Two Phase 3 wins put COMP360 before the FDA. Can Compass Pathways turn psilocybin into a mainstream depression treatment?

Compass Pathways has completed its COMP360 psilocybin NDA after two positive Phase 3 trials, setting up a major FDA test in resistant depression.

Read More
Pharma & Biotech

Compass Pathways has stronger COMP360 data, but can psilocybin treatment scale?

Find out how Compass Pathways’ COMP360 Phase 3 data could shape regulated psilocybin treatment for depression.

Read More
Pharma & Biotech

Why Compass Pathways’ upcoming COMP360 data could redefine late-stage psychedelic drug development

Compass Pathways is set to release pivotal Phase 3 COMP360 data in treatment-resistant depression. Find out why this readout could reshape psychedelic drug development.

Read More